Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Mar 5;190(9):E247-E257.
doi: 10.1503/cmaj.170958.

Management of opioid use disorders: a national clinical practice guideline

Julie Bruneau  1 , Keith Ahamad  2 , Marie-Ève Goyer  2 , Ginette Poulin  2 , Peter Selby  2 , Benedikt Fischer  2 , T Cameron Wild  2 , Evan Wood  2 ; CIHR Canadian Research Initiative in Substance Misuse
Affiliations
Practice Guideline

Management of opioid use disorders: a national clinical practice guideline

Julie Bruneau et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Julie Bruneau, Benedikt Fischer, T. Cameron Wild, and Evan Wood report grants from the Canadian Institutes of Health Research (CIHR) during the conduct of the study. Peter Selby reports grants from CIHR to the Centre for Addiction and Mental Health during the conduct of the study. Peter Selby conducted an expert review for the Canadian Agency for Drugs and Technologies in Health on a rapid analysis for a formulation of buprenorphine in the last 12 months. Marie-Ève Goyer reports payments from Indivior, Gilead Sciences, ViiV Healthcare and Merck, outside of the submitted work. Julie Bruneau reports monetary compensation as advisor from Gilead and Merck, outside of the submitted work. No other competing interests were declared.

Figures

Figure 1:
Figure 1:
Treatment algorithm for opioid use disorder. Note: A particular medication may not be indicated for a variety of reasons, including ineffectiveness or medical contraindication, comorbidities, drug–drug interactions, patient preference and specific circumstances, and prescriber’s experience. Any treatment for opioid use disorder, but particularly slow agonist tapers, should incorporate evidence-based psychosocial interventions with qualified professionals, motivational interviewing, long-term monitoring of substance use, provision of comprehensive primary care, and referrals to psychosocial treatment interventions and psychosocial supports as appropriate, with specialist care as required, to optimize physical and mental wellness as the patient progresses in recovery. Withdrawal management (formerly “detoxification”) without linkage to long-term addiction treatment is to be avoided, and patients desiring such approach should be informed of risks and encouraged toward other treatment options that would suit their circumstances. DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, fifth edition.
See this image and copyright information in PMC

Comment in

References

    1. Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy 2017;46:172–9. - PMC - PubMed
    1. Canadian Institute for Health Information, Canadian Centre on Substance Abuse. Hospitalizations and emergency department visits due to opioid poisoning in Canada. Ottawa: Canadian Institute for Health Information; 2016.
    1. Bruneau J, Roy E, Arruda N, et al. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012;107:1318–27. - PubMed
    1. Hadland SE, DeBeck K, Kerr T, et al. Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. BMJ Open 2014;4:e005419. - PMC - PubMed
    1. Lankenau SE, Kecojevic A, Silva K. Associations between prescription opioid injection and hepatitis C virus among young injection drug users. Drugs (Abingdon Engl) 2015;22:35–42. - PMC - PubMed

Publication types

MeSH terms

Substances